Drug Type Monoclonal antibody |
Synonyms IAH0968 |
Target |
Action modulators |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 3 | China | 15 Aug 2024 | |
Colorectal Cancer | Phase 3 | China | 15 Aug 2024 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | China | 15 Aug 2024 | |
Hepatocellular Carcinoma | Phase 3 | China | 15 Aug 2024 | |
Malignant neoplasm of gastro-oesophageal junction | Phase 3 | China | 15 Aug 2024 | |
Metastatic Gastric Carcinoma | Phase 3 | China | 15 Aug 2024 | |
Metastatic Solid Tumor | Phase 3 | China | 15 Aug 2024 | |
HER2 Positive Cancer | Phase 3 | China | 19 Jul 2024 | |
HER2-positive gastric cancer | Phase 3 | China | 19 Jul 2024 | |
HER2 Positive Colorectal Cancer | Phase 3 | China | 12 May 2023 |
NCT04934514 (ASCO2023) Manual | Phase 1 | HER2 Positive Solid Tumors HER2 Positive | 18 | bcgskilriv(xkelsybuef) = aecpaydcni oqsjbpdkcw (lccvsbbwta ) View more | Positive | 31 May 2023 |